Na Wang1, Yaozhong Zhang2, Yuan Mi2, Haowen Deng2, Ge Chen2, Zilong Tang2, Junjie Mao2, Saijin Cui1, Yaling Zhang1, Lei Wang3. 1. Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. 2. Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. 3. Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. yuankundu@163.com.
Abstract
BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI. Osimertinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Osimertinib is used to treat a certain type of non-small cell lung cancer. We review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, activity of osimertinib penetrating blood-brain barrier and the efficacy of osimertinib. METHODS: Guided by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement, we conducted a systematic literature search in the databases PubMed, EMBASE, ISI Web of Science database on January 30, 2020, searching for studies investigating the osimertinib efficacy on patients with CNS metastases in EGFR-mutant non-small cell lung cancer (NSCLC). And Newcastle-Ottawa Scale (NOS) was used to assess the certainty in the evidence. RESULTS: The pooled results showed that the overall response rate (ORR) and disease control rate (DCR) were 70% and 92%, respectively, in patients with T790M mutations. The efficacy of osimertinib was confirmed by the median progression free survival (PFS). In untreated advanced EGFR-mutated NSCLC with CNS metastases patients, the pooled ORR and DCR of osimertinib were 71% and 93%, respectively. And the combined median PFS, achieved by osimertinib, was 12.21 months. Above data proved that osimertinib has well activity in disease control, especially in first line. CONCLUSIONS: This meta-analysis confirmed that in treatment-naive advanced NSCLC CNS metastases harboring EGFR-TKI-sensitizing mutations, Osimertinib showed impressive antitumor activity.
BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI. Osimertinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Osimertinib is used to treat a certain type of non-small cell lung cancer. We review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, activity of osimertinib penetrating blood-brain barrier and the efficacy of osimertinib. METHODS: Guided by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement, we conducted a systematic literature search in the databases PubMed, EMBASE, ISI Web of Science database on January 30, 2020, searching for studies investigating the osimertinib efficacy on patients with CNS metastases in EGFR-mutant non-small cell lung cancer (NSCLC). And Newcastle-Ottawa Scale (NOS) was used to assess the certainty in the evidence. RESULTS: The pooled results showed that the overall response rate (ORR) and disease control rate (DCR) were 70% and 92%, respectively, in patients with T790M mutations. The efficacy of osimertinib was confirmed by the median progression free survival (PFS). In untreated advanced EGFR-mutated NSCLC with CNS metastases patients, the pooled ORR and DCR of osimertinib were 71% and 93%, respectively. And the combined median PFS, achieved by osimertinib, was 12.21 months. Above data proved that osimertinib has well activity in disease control, especially in first line. CONCLUSIONS: This meta-analysis confirmed that in treatment-naive advanced NSCLC CNS metastases harboring EGFR-TKI-sensitizing mutations, Osimertinib showed impressive antitumor activity.
Entities:
Keywords:
EGFR-mutant lung cancer; Osimertinib; central nervous system metastases; meta-analysis
Authors: Andrés F Cardona; Daniel Jaramillo-Velásquez; Alejandro Ruiz-Patiño; Carolina Polo; Enrique Jiménez; Fernando Hakim; Diego Gómez; Juan Fernando Ramón; Hernando Cifuentes; Juan Armando Mejía; Fernando Salguero; Camila Ordoñez; Álvaro Muñoz; Sonia Bermúdez; Nicolas Useche; Diego Pineda; Luisa Ricaurte; Zyanya Lucia Zatarain-Barrón; July Rodríguez; Jenny Avila; Leonardo Rojas; Elvira Jaller; Carolina Sotelo; Juan Esteban Garcia-Robledo; Nicolas Santoyo; Christian Rolfo; Rafael Rosell; Oscar Arrieta Journal: J Neurooncol Date: 2021-09-09 Impact factor: 4.130